NOVAX PHARMA

What NOVAX PHARMA does

NOVAX PHARMA (legal entity Novax Pharma S.A.M.) is a privately held ophthalmic medical device company founded in 2008 and headquartered in Monaco. The company formulates, manufactures, markets, and distributes a portfolio of eye care solutions organized across five categories: lubricating eye drops and sprays (LUXYAL®, VISIONLUX®, NAVITAE®, NAVILIPO®, LACTO®), natural-formulation products (FLORA VISION® line), preservative-free products using OSD squeeze-dispenser technology (VERBALUX® PF, NAVITAE® PLUS PF, NAVI®NaCl), eyelid hygiene products for blepharitis (NAVIBLEF® TTO and TERP lines), and multi-purpose contact lens solutions (LUXCLEAR®). Core technological differentiators include the SCO® (Stabilized Complex Oxychloro) preservative system, P-Plus™ bioadhesive lubricant, cross-linked Sodium Hyaluronate, and Tea Tree Oil/Terpinen-4-ol formulations targeting Demodex-related blepharitis.

The company's commercial model relies on a global network of independent distributors supplemented by direct engagement with eye specialists and medical professionals, with marketing concentrated at industry conferences (SFO, CPHI) and via LinkedIn, Facebook, and Instagram. NOVAX PHARMA holds ISO 13485 certification (since 2016), CE marking across its product line, and an MDD/MDR extension continuity grant through December 2028, providing a defensible regulatory position in European markets. In 2021, the company created VITEVAX®PHARMA as a wholly-owned subsidiary to diversify into eye care food supplements, cosmetics, and disinfecting products. End customers include patients with dry eye syndrome, blepharitis, and corneal conditions, as well as contact lens wearers, with healthcare professionals and government healthcare systems as procurement channels. Revenue, headcount, and pricing are not publicly disclosed.

Name

NOVAX PHARMA

Legal name

Novax Pharma S.A.M.

Website

https://novaxpharma.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

NOVAX PHARMA is a privately held Monaco-based ophthalmic medical device company founded in 2008 that formulates, manufactures, and globally distributes a proprietary portfolio of eye drops, sprays, eyelid cleansers, and contact lens solutions — serving patients with dry eye, blepharitis, and corneal conditions through an international distributor network.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851)

akta.pro industry

PRIMARYHLAHAJAE

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

SECONDARYHLAHAIAL

Ocular Drug Delivery Devices (Eye Droppers/Inserts)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

• Ophthalmic medical devices
• Dry eye treatment
• Contact lens solutions
• Blepharitis treatment
• Eye care formulations

Headquarters

HQ city

Monaco

HQ country

Monaco

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Products (Ophthalmic): NOVAX PHARMA generates revenue through the manufacture, marketing, and distribution of ophthalmic medical devices including eye drops, eye sprays, eyelid cleansing products, and contact lens solutions. Products are sold through global distributor networks and directly to medical professionals, patients, and government healthcare systems.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

NOVAX PHARMA formulates, manufactures, markets, and distributes ophthalmic medical devices including lubricating eye drops, eye sprays, eyelid cleansing foams for blepharitis, preservative-free formulations, and multi-purpose contact lens solutions. The company sells its CE-marked, ISO 13485-certified products through an international distributor network to medical professionals, patients, and government healthcare systems globally. In 2021, it extended into adjacent eye care segments (food supplements, cosmetics, disinfecting products) via its VITEVAX®PHARMA branch.

Product overview

NOVAX PHARMA is an innovative ophthalmic medical device company offering a comprehensive portfolio of eye care solutions organized into five main product categories: moisturizing and lubricating eye drops/sprays (LUXYAL®, VISIONLUX®, NAVITAE®, NAVILIPO®, LACTO®), natural formulation products (FLORA VISION® line for dry, irritated, and red eyes), preservative-free products using OSD technology (VERBALUX® PF, NAVITAE® PLUS PF, NAVI®NaCl), eyelid hygiene products for blepharitis (NAVIBLEF® TTO and TERP lines), and multipurpose contact lens solutions (LUXCLEAR®). The products share common proprietary technologies including SCO® (Stabilized Complex Oxychloro) preservative system and P-Plus™ bioadhesive lubricant. The company also operates VITEVAX®PHARMA as a separate division for food supplements and cosmetics.

Differentiator

Problem solved

Functional benefit

Brands

• VITEVAX®PHARMA: Specialized in the development of Eye Care Food Supplements, Eye Care Cosmetics and Eye Care disinfecting and cleansing products for the comfort of the eye.

Products and services

• LUXYAL® PLUS Lubricating eye drops containing Sodium Hyaluronate 0.3% with P-Plus and SCO preservative system, formulated for long-lasting relief of dry eye symptoms.
• VISIONLUX® PLUS Lubricating ophthalmic solution with Sodium Hyaluronate 0.3%, P-Plus, Vitamin B12, and SCO system, indicated for severe dry eye treatment.
• NAVITAE® PLUS Lubricant ophthalmic solution with antioxidant and moisturizing effect containing Sodium Hyaluronate 0.15%, Carboxymethyl Beta-Glucan, Vitamin A and E for dry eye relief.
• NAVILIPO® Liposomal ophthalmic solution with phospholipids, Sodium Hyaluronate, and Aloe Vera designed to restore the lipid layer of the tear film.
• NAVILIPO® SPRAY Lipid-containing artificial tear spray for restoring the protective layer of the tear film.
• LACTO® Eye drops with Lactoferrin and HPMC for relief of dry eye and inflammatory symptoms, using an endogenous preservative system.
• LUXYAL® CROSS-LINK Gel tears combining cross-linked Sodium Hyaluronate with P-Plus demulcent using dual polymer technology for extended surface retention.
• FLORA VISION® DRY EYES Natural formulation eye drops with Sodium Hyaluronate, Aloe Vera, and electrolytes for quick and lasting relief from dry and tired eyes.
• FLORA VISION® IRRITATED EYES Natural eye drops with Calendula, Hamamelis, and Plantago extracts for relief of eye irritation and minor allergies.
• FLORA VISION® RED EYES Natural eye drops with Chamomile, Euphrasia, and Curcuma extracts for relief of red and tired eyes with conjunctivitis-like symptoms.
• FLORA VISION® DRY EYE SPRAY Spray formulation with natural ingredients for relief of dry eye symptoms caused by external factors.
• FLORA VISION® IRRITATED EYE SPRAY Spray formulation with natural plant extracts for relief of eye irritation due to allergies.
• FLORA VISION® RED EYE SPRAY Spray formulation with Chamomile, Euphrasia, and Curcuma for relief of red eyes.
• NAVI®INFLA Antioxidant and lubricating ophthalmic solution with Rosa damascena, Emblica officinalis, and Curcuma longa for relief of conjunctivitis symptoms and inflammation.
• NAVI®NaCl Hypertonic ophthalmic solution (Sodium Chloride 5%) using OSD technology for alleviation of corneal oedema symptoms.
• VERBALUX® PF Preservative-free lubricating ophthalmic solution with cross-linked Sodium Hyaluronate, Verbascoside, and electrolytes for corneal healing support.
• NAVITAE® PLUS PF Preservative-free antioxidant and lubricant ophthalmic solution with Sodium Hyaluronate, Carboxymethyl Beta-glucan, and Vitamins A and E.
• NAVIBLEF® TTO INTENSIVE CARE Eyelid cleansing foam with high-concentration Tea Tree Oil for mechanical removal of severe ocular secretions caused by Demodex or bacterial infestations.
• NAVIBLEF® TTO DAILY CARE Daily eyelid cleansing foam with Tea Tree Oil for maintenance care after intensive blepharitis treatment.
• NAVIBLEF® TERP INTENSIVE CARE Eyelid cleansing foam with Terpinen-4-ol for efficient removal of severe ocular secretions from blepharitis and Demodex.
• NAVIBLEF® TERP DAILY CARE Daily maintenance eyelid cleansing foam with Terpinen-4-ol for ongoing blepharitis care.
• LUXCLEAR® Multi-purpose solution with Pluronic, disodium edetate, and PHMB for cleaning, decontamination, and protein removal from soft contact lenses.
• VITEVAX®PHARMA Eye Care Product Line Branch product line specializing in Eye Care Food Supplements, Eye Care Cosmetics, and Eye Care disinfecting and cleansing products for the comfort of the eye, launched as an extension of NOVAX PHARMA in 2021.

Quantifiable outcome

• Improves tear break-up time (TBUT) and symptoms in severe dry-eye patients
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered moderate and core.

• Monaco Economic Board (MEB)moderateOthers · 6 May 2023The Monaco Economic Board facilitated media opportunities for NOVAX PHARMA, with Deputy CEO Justin Highman conducting joint radio interviews with General Manager Brigitte Dias Ferreira on Radio Riviera and Radio Monaco to promote the company's innovative products.
• Research Centre Italy (Rome)coreStrategic or Co-development PartnerCollaboration with scientists and doctors from Italian research centres, specifically located in Rome, for product development and innovation in ophthalmic formulations.
• Research Centre France (Sophia-Antipolis)coreStrategic or Co-development PartnerPartnership with scientific and medical researchers based at Sophia-Antipolis technology park in France for ophthalmic research and product innovation.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• OCuSOFT: US-based privately held ophthalmic company specializing in lid hygiene (Oust Demodex), dry eye, and ocular surface products. Directly comparable in the blepharitis/Demodex niche.
• TRB Chemedica: Smaller specialty ophthalmic company with hyaluronic-acid-based eye drops and ocular surface products in European and international markets. Similar size band and product positioning.
• Théa Laboratories: Privately held, family-owned specialty ophthalmic company headquartered in France with a comparable product mix spanning artificial tears, lid hygiene, and ocular surface therapeutics. Closest functional peer in size, geography, and distribution model.
• Scope Ophthalmics: UK-based specialty eye-care company marketing lid hygiene (Blephagel), dry eye, and preservative-free products through European distributors. Closely comparable niche focus and distribution model.
• Santen Pharmaceutical: Japan-headquartered specialty ophthalmology company selling prescription and OTC ophthalmic products globally. Comparable product overlap in dry eye and ocular surface, though at significantly larger scale.
• Ursapharm: German specialty ophthalmic company focused on preservative-free eye drops and lid hygiene products. Comparable mid-sized independent operator with a similar European regulatory and distributor-driven GTM.

Broad incumbents

• Bausch + Lomb: Global eye-care major with broad portfolios in artificial tears (Artelac, Soothe), contact lens solutions (Biotrue, Renu), and lid hygiene. Directly overlaps every NOVAX product category but at vastly larger scale.
• Alcon: World's largest eye-care company with leading positions in surgical, vision care, and dry-eye (Systane) categories. Competes across NOVAX's full portfolio with much greater R&D and marketing resources.
• Allergan / AbbVie Eye Care: AbbVie's ophthalmology franchise (formerly Allergan) markets Refresh artificial tears and Restasis; competes in the same ocular surface categories as NOVAX with global reach and significant promotional investment.

Emerging players

• Nicox: European ophthalmology specialty company focused on novel therapeutics for ocular surface and glaucoma. Comparable innovation-driven positioning with partial overlap in dry-eye therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Novax-Pharma-1669408160010074
• LinkedInlinkedin.com/company/novax-pharma
• Instagraminstagram.com/novaxpharma/?hl=fr

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOVAX PHARMA